Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website https://www.gastrores.org

Short Communication

Volume 16, Number 4, August 2023, pages 240-243

A Significant Effect of Pemafibrate on Hepatic Steatosis and Fibrosis Indexes in Patients With Hypertriglyceridemia

Figure

Figure 1. Correlations between the baseline values and the changes of hepatic steatosis index (HSI), nonalcoholic fatty liver disease (NAFLD) fibrosis score (NFS), aspartate aminotransferase (AST) to platelet ratio index (APRI) and FIB-4 index during the 1-year pemafibrate treatment.

Table

**Table 1.** Changes in the Indexes for Hepatic Steatosis and Fibrosis at 1 Year After the Start of Pemafibrate
Variables	N	Baseline	12 months	P value
APRI: aspartate aminotransferase (AST) to platelet ratio index; HSI: hepatic steatosis index; NFS: nonalcoholic fatty liver disease (NAFLD) fibrosis score.
HSI	94	40.1 ± 9.7	38.3 ± 6.8	< 0.001
NFS	82	-0.81 ± 1.21	-0.90 ± 1.30	0.135
APRI	127	0.43 ± 0.73	0.30 ± 0.22	< 0.001
FIB-4 index
All patients	123	1.61 ± 1.94	1.43 ± 0.80	0.882
Baseline FIB-4 index ≥ 1.45	53	2.55 ± 2.66	2.03 ± 0.83	0.042
Baseline FIB-4 index <1.45	70	0.91 ± 0.30	0.98 ± 0.27	0.043